OSTEOPOROSIS:
How Effective is Prevention?
by
Maryann Napoli
When
osteoporosis emerged as a major health problem in the 1980s,
experts in the field believed that the devastating fractures
suffered by some women in old age could be prevented. Most
of the diet and exercise advice was aimed at mid-life women
who were warned that they would be rapidly losing bone right
after menopause. The bone loss, they were told, was largely
due to the body's declining level of estrogen. In time,
bone density testing became a rite of passage for many menopausal
women.
The
increased awareness of osteoporosis plus the overemphasis
on estrogen's role in bone loss had the unfortunate consequence
of making mid-life women believe that an inevitable hip
fracture loomed in the near future. Once bone density testing
continued to show bone loss, something had to be done. And
that something often turned out to be a lifelong
prescription for estrogen. This hormone drug proved itself
many times over to be good at stopping bone loss. However,
estrogen had never been proven to reduce the fracture rate.
That
proof arrived in 2002 with the results from the Women's
Health Initiative (WHI) trial. Estrogen, in combination
with progestin, slightly reduced the rate of hip fractures
in the WHI. Unfortunately, this hormone combination is too
risky for lifelong use because the WHI showed that it raised
the risk of developing blood clots, stroke, breast cancer
and Alzheimer's disease. (Progestin was added to the regimen
to protect the uterus from estrogen's cancer-causing effect.)
Now,
the tide of expert opinion is slowly changing its focus
away from mid-life women to those of advanced age. As Dr.
Susan Love said in her Menopause & Hormone Book, “The
usual line is that prevention is always better than treatment,
and this has certainly driven the use of HRT [hormone replacement
therapy] in postmenopausal women. This may not actually
be the case.”
Dr.
Love sees the newer osteoporosis medication--from a drug
class known as the bisphosphonates (brand names: Fosamax,
Actonel, Didronel)--as safer alternatives to 30 years on
estrogen.
Bisphosphonates
will modestly reduce the hip and spinal fracture rate, but
the published evidence for this benefit is primarily confined
to elderly women with low bone mineral density and at least
one other major risk, such as a previous spinal fracture.
An
osteoporosis-related hip fracture is rare in women younger
than 70 (the average age at which it occurs in women is
79), and only 18% of all white women will ever have a fracture.
One reason to reserve treatment for high-risk older women
is the lack of long-term information--beyond seven years--about
bisphosphonate's safety and continued effectiveness.
The
shift in thinking about osteoporosis prevention is reflected
in the revised recommendations about when to start bone
density testing. Several medical organizations, such as
the National Osteoporosis Foundation, now suggest that women
not start until age 65, unless they are at extremely high
risk. Some osteoporosis researchers have made a case for
the quality of bone strength as the more important indicator
of a future fracture than bone density. There is no available
test for bone strength.
How
Good are the Best Drugs?
The
bisphosphonates cannot improve bone strength, but they are
the only drugs proven to reduce the rate of hip and spinal
fractures. Actonel, for example, modestly reduced the fracture
rate in a study of 10,000 high-risk elderly women with low
bone density or osteoporosis and at least one risk factor
for hip fracture, such as an unsteady gait. At three years,
there was a 1% lower rate of hip and spinal fractures among
the women taking Actonel than those taking the placebo.
Interestingly, the three-year fracture rate was low in these
supposedly high-risk women, even among those not taking
the drug. Overall, the fracture rate was 4% among those
taking a placebo versus 3% among those on Actonel (New England
Journal of Medicine, 2/1/01).
The
fracture prevention value of bisphosphonates in younger
women is yet to be demonstrated. In another trial, 1,609
postmenopausal participants, aged 45 to 59 years, were chosen
because they did not have osteoporosis. Short-term treatment
with Fosamax (5 mg/daily or 2.5 mg/daily) was compared with
estrogen plus progestin. The idea was to see whether Fosamax
had a sustained effect once the drug was discontinued. The
study was paid for in part by a grant from Merck, maker
of Fosamax. Some of the women in the Fosamax group took
the drug for two years and were than switched to a placebo;
others remained on the drug for the four-year duration of
the study.
At
the end of this study, bone loss had been prevented in those
taking Fosamax and in those on estrogen/progestin. Continuous
Fosamax treatment, however, was more effective in preventing
bone loss than the shorter two-year regimen. The fracture
rate is low in this age group, and the study lasted only
four years; therefore, this trial could not show that Fosamax
reduced fractures (Annals of Internal Medicine, 12/21/99).
What
about Diet and Exercise?
Osteoporosis
research has clearly shown that increased calcium intake
and certain exercises will stop bone loss and/or improve
bone density, but few studies have lasted long enough to
prove the ultimate goal of fracture reduction. In 2002,
the Cochrane Library published an updated review of all
studies that assessed the value of exercise in preventing
osteoporosis. The reviewers conclusions favored aerobics,
weight bearing and resistance exercises as the most effective
in increasing bone mineral density of the spine. And walking
was effective for the hip. Of the few studies that showed
fracture reduction, two found walking to be the best for
older men and women. In fact, a moderate amount
of walking (2-4 hours a week), and even standing, reduced
the hip fracture rate. Interestingly, one study showed that
the people who spent more time walking did not have a lower
rate of fractures than those did just the 2-4 hours a week.
Where
diet is concerned, emphasis has been almost entirely--and
perhaps, inappropriately--placed on calcium. For over 20
years, women have been advised to increase their daily calcium
intake with diet and/or supplements to 1,000 mg daily, and
then raise it to 1,500 mg after age 50.
Studies
show that calcium supplements will stop bone loss, but they
typically did not last long enough to provide information
about fractures. As for any fracture-reduction benefit from
high dietary calcium intake, the famed Nurses'
Health Study produced some bad news. About 77,000 of the
participants were singled out because they did not take
calcium supplements. All were between the ages of 30 and
55 years in 1980 when they began filling out extensive questionnaires
biannually about their health habits. After 18 years, there
was a modest but significantly increased incidence of
fracture among the women who reported the highest
dietary intake of calcium, primarily from milk and other
dairy foods (American Journal of Public Health, 6/97).
To
determine whether this study was an aberration, Diane Feskanich,
D.Sc., and colleagues at Harvard Medical School, looked
at all the trials in which calcium supplementation was compared
to a placebo, as well as the longer studies, such as the
Nurses' Health Study, in which women were asked about their
diet, calcium supplement usage and other health habits while
being followed for many years. The Harvard researchers concluded
that the first category of trials, those that lasted only
a few years, typically showed that calcium supplements reduced
bone loss. But “the longer observational studies did not
generally find a lower risk of hip fracture with higher-calcium
diets” (American Journal of Clinical Nutrition, 2/03).
In
a telephone interview, Dr. Feskanich was asked why women
continue to be told to increase their calcium intake. “Calcium's
importance is overrated--–we have a strong milk industry
[in this country], and the U.S. Department of Agriculture
was started with the mission to promote the idea that certain
foods, especially dairy foods, must be consumed,” she answered,
adding the importance of the Dairy Council, which has had
a major influence on doctors as well as the general public.
Contradictions abound. “We know from worldwide population
studies that the high-calcium intake is associated with
high hip fracture rates--Scandinavian countries, for example,”
Dr. Feskanich continued, noting that Asian and Mediterranean
countries with very low calcium intake have low fracture
rates.
Vitamin
A
The
emphasis on the importance of calcium has led many women
to drink low-fat or non-fat milk to prevent osteoporosis,
a practice that is counterproductive, according to Dr. Feskanich.
Drawing, once again, from 18-year data provided by the Nurses'
Health Study, Dr. Feskanich and her colleagues found that
a certain type of vitamin A, is associated with an increase
in hip fractures (JAMA, 1/2/02). They identified the fortification
of dairy products as the chief culprit. “Because the fat
has been removed, the vitamin A has to be put back,” explained
Dr. Feskanich, adding that people typically take a one-a-day
vitamin supplement and eat a fortified breakfast cereal,
and they might eat a power bar--all of which are fortified
with vitamin A.
The
fortification is usually done with the cheaper form of the
vitamin called retinol, the type that is not good for bones
in the long term, according to Dr. Feskanich. You can get
beta carotene [the other form of vitamin A] from orange
and yellow vegetables and fruits, she added, “and you can
get plenty without eating animal products or taking a supplement.”
Consumption of just one multivitamin often provides an excessive
amount of vitamin A if the label says 5,000 IU with retinol
as the major source. But some vitamin manufacturers have
begun to reduce or eliminate retinol from their products.
To
Dr. Feskanich and other nutrition researchers, the current
RDA of 5,000 IU daily of vitamin A is too high, a point
made in the editorial that accompanied her study. The editorial
cites, approvingly, the Institute of Medicine's new recommendations
for vitamin A intake as 800 IU daily for men and 700 IU
daily for women.
Vitamin
D
At
the end of the telephone interview, Dr. Feskanich said,
“I can't say that there is no benefit to calcium,
but I think there's a bigger benefit from vitamin D.” Unfortunately,
Dr. Feskanich and colleagues found that only a few studies
focused on this vitamin as a way to prevent fractures. One
of them, published in 2003 in the British Medical Journal,
had over 2,600 participants, aged 65 to 85 years at the
onset. All were living in the community (as opposed to a
nursing home) and had been randomly assigned to take a placebo
or vitamin D.
The
study was conducted entirely by mail. The participants were
sent one capsule containing 100,000 IU of vitamin D3 (cholecalciferol)
or a placebo every four months for five years. The total
fracture incidence was reduced by 22%. The research team
led by Daksha P. Trivedi cautioned that the fracture incidence
was extremely low even in those who had been taking the
placebo, possibly due to the fact that most of the participants
were men.
This
was a small pilot study, and as such cannot be considered
the last word on the role of vitamin D and fracture prevention.
Dr. Trivedi and colleagues wrote, “The results, nonetheless,
indicate that isolated vitamin D supplementation prevents
fractures.” In discussing their findings, Dr. Trivedi and
colleagues wrote that the every-four-month dose of 100,000
IU averages out to be a daily equivalent of 800 IU of vitamin
D. And this might explain why their results were different
from those of earlier trials, which used a lower dose (400
IU) and found no fracture-reduction benefit due to vitamin
D.
The
rapid responses to this article, or letters to the editor,
can be read at no charge on the British Medical Journal's
Web site (www.bmj.com,
see March 1,2003). Several raised the concern about the
potential toxicity of high doses of vitamin D. This was
answered by one of the study's co-authors, Kay Tee Shaw,
who wrote that several earlier trials showed that extremely
high doses of vitamin D are safe. In one Scandinavian trial,
nursing home residents were safely given single-dose injections
of 300,000 IU of vitamin D annually for four to five years.
Dr.
Feskanich's response to the same concern was that vitamin
D is fat-soluble so people don't need to take a little bit
every day. What's more, “vitamin D is stored in the liver,
and this is good,” she explained, because elderly people
don't metabolize vitamins well as they age, and the body's
capacity to produce vitamin D when exposed to sunlight also
declines with age. Her studies found that women typically
consume less than the recommended intake of vitamin D. Therefore,
they should consider supplement use or dark fish consumption.
--
Maryann
Napoli is the associate director of the Center for Medical
Consumers in New York City.
December
2003